Shin Hatou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellusion Receives U S FDA Orphan Drug Designation for CLS001

Cellusion Receives U S FDA Orphan Drug Designation for CLS001
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesShin hatouDepartment of ophthalmologyIcellusion incKeio university school of medicineDrug administrationDrug designationOrphan drug designationSearch orphan drug designationsCorneal endothelial cell substituteKeio university schoolMore smiles

Cellusion raises 2 83 Billion Yen (21 Million USD) in Series C Round

Cellusion raises 2 83 Billion Yen (21 Million USD) in Series C Round
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hiroaki kobayashiFosun pharmaShin hatouNorio takadaJunichi imotoYoshiharu asaiShigeto shimmuraKeio university hospitalGemseki incInnovation fundHead officeVenture capital co ltdMirai creation fundAxil capital partnersCapital co ltdIcellusion inc

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyMinari allendaleHidehito takahashiNoriko takadaHiroto bandoShin hatouMinaris regenerative medicineKeio university school of medicineWorld health organizationIcellusion incUn sustainable development goalsShowa denko materials co ltdKeio university hospitalDepartment of ophthalmologyCorneal endothelial cell substitute

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 f

Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights.The Deal is Worth up to over $100 Million, including Upfront, Development and Sales Milestone Payments, and Tiered Royalties.TOKYO & HANGZHOU, China & SHANGHAI (B.

United statesHong kongWen deyongJoji hayashidaJialei maShin hatouFosun pharmaCui zhipingKeio university school of medicineSinopharm co ltdShanghai fosun pharmaceutical group co ltdFosun health capitalDrug fundHangzhou celregen therapeutics ltdIcellusion incDrug fund of fosun health capital

Celregen signs license deal with Cellusion for bullous keratopathy therapy

Shanghai Fosun Pharmaceutical has entered into an exclusive license agreement with Japanese regenerative medicine start-up Cellusion for CLS001.

Hong kongShin hatouFosun pharmaCui zhipingKeio university hospitalGreater chinaFirst in human investigator initiated study